Expert: U.S.-Australian FTA could increase drug prices 30%

05/21/2004 | Age (Melbourne, Australia), The

An American expert on international drug pricing said the free-trade agreement signed this week between the two countries favors American drug companies and would raise Australian drug prices 30% in about five years. Opponents of the agreement have argued the establishment of a review committee to review complaints from firms whose medicines are not listed on the Pharmaceutical Benefits Scheme (PBS) would give U.S. drug firms the ability to push prices higher or delay the addition of generic drugs to the PBS.

View Full Article in:

Age (Melbourne, Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care